Online inquiry

IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7327MR)

This product GTTS-WQ7327MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FGFR2 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000141.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2263
UniProt ID P21802
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ7327MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15513MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ11776MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ4395MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ7481MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GC-1008
GTTS-WQ8010MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GZ-402668
GTTS-WQ1466MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ6349MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ14403MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW